Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune cell and cytokine changes in psoriasis patients treated with secukinumab
ChiCTR2200064706Phase 4Recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in psoriasis, sponsored by Second Hospital of Shandong University. Primary endpoints: Treg/TH1/TH2/TH17 immune cells, Inflammatory cytokines (IFN-γ, TNF-α, IL-10, IL-12, IL-17, IL-23, etc.) and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR2200064706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064706.